Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.

Publication Type:

Journal Article

Source:

The Journal of infectious diseases, Volume 202, Issue 5, p.734-8 (2010)

Keywords:

2010, Acyclovir, Adult, Antibodies, Viral, Antiviral Agents, CD4 Lymphocyte Count, Center-Authored Paper, Female, Herpes Genitalis, Herpesvirus 2, Human, HIV Infections, HIV Reverse Transcriptase, HIV-1, Humans, Male, RNA, Viral, Treatment Outcome, Vaccine and Infectious Disease Division, Viral Load, Young Adult

Abstract:

We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse-transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons (HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (P =.30) or CD4 cell counts (P =.85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.